SBI Card
Anand Rathi
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 27 Jan 2022 | SBI Cards and Payment |
Anand Rathi
|
919.35 | 1221.00 | 896.00 (2.61%) |
Buy
|
|||||
| 27 Jan 2022 | Sharda Cropchem |
Anand Rathi
|
699.30 | 600.00 | 602.35 (16.10%) | Target met |
Buy
|
||||
| 27 Jan 2022 | SBI Life Insurance |
Anand Rathi
|
1806.80 | 1504.00 | 1220.10 (48.09%) |
Buy
|
|||||
| 24 Jan 2022 | Sonata Software |
Anand Rathi
|
406.40 | 1050.00 | 819.80 (-50.43%) | Pre-Bonus/ Split |
Buy
|
||||
| 06 Oct 2020 | Amara Raja Energy |
Anand Rathi
|
1058.20 | 907.00 | 741.00 (42.81%) | Target met |
Buy
|
||||
| 30 Sep 2020 | Sudarshan Chemical |
Anand Rathi
|
1090.90 | 585.00 | 484.65 (125.09%) | Target met |
Buy
|
||||
| 23 Sep 2020 | KEC International |
Anand Rathi
|
872.40 | 398.00 | 309.15 (182.19%) | Target met |
Buy
|
||||
| 20 Aug 2020 | Deccan Cements |
Anand Rathi
|
762.85 | 458.00 | 289.20 (163.78%) | Target met |
Buy
|
Deccan Cements
Anand Rathi
Good operating show; WHRS to aid savings; retaining a Buy Amid the tough business environment, Deccan Cements reported an enhanced operating performance, beating our estimates, aided by price hikes and cost savings, though the volume decline was in line with the industry. On the commencement of the 6MW WHRS, savings in fuel costs are expected to aid its operating performance. The GU expansion is currently on hold. We believe it strong net cash balance sheet and current short term profitability augurs well. We retain our Buy...
|
|||
| 18 Aug 2020 | Cohance Lifesciences |
Anand Rathi
|
1099.90 | 760.00 | 678.15 (62.19%) | Target met |
Buy
|
Suven Pharma
Anand Rathi
Valuation. At the CMP of `652, the stock trades at 22.1x, 18.3x and 15.5x respective FY21e/22e/23e earnings. We retain our Buy recommendation, with a higher price target of `760 (earlier `695), based on 18x FY23e EPS. Risks:...
|
|||
| 18 Aug 2020 | Mayur Uniquoters |
Anand Rathi
|
589.40 | 337.00 | 278.80 (111.41%) | Target met |
Buy
|
Mayur Uniquoter
Anand Rathi
plant and exports are behind (reasons for a de-rating over the last two years), at ~10x FY22e P/E, we believe in good scope for a re-rating given improving prospects. Its net-cash status and FCF generation ability even in the downturn are other positives. While the near-term outlook is challenging, we are positive...
|
|||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.